Related Experiment Video
Updated: Mar 7, 2026
10:01
Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
Published on: October 17, 2018
8.5K
Prospects for a Zika Virus Vaccine
Dan H Barouch1, Stephen J Thomas2, Nelson L Michael3
1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Immunity
|February 24, 2017
Summary
Developing a Zika virus (ZIKV) vaccine is a global health priority due to recent outbreaks. Promising preclinical data exist, but challenges in vaccine development and clinical evaluation remain.
Area of Science:
- Virology
- Vaccinology
- Public Health
Background:
- The Zika virus (ZIKV) outbreak in the Americas has been linked to severe health issues, including microcephaly in infants and Guillain-Barre syndrome in adults.
- These ZIKV-associated conditions underscore the urgent need for a safe and effective vaccine.
Purpose of the Study:
- To review the current status of Zika virus vaccine development.
- To discuss various vaccination strategies and identify challenges in evaluating ZIKV vaccine candidates.
Main Methods:
- Review of preclinical vaccine studies in relevant animal models (mice and non-human primates).
- Analysis of different vaccine platforms and immunogenic approaches for ZIKV.
- Examination of hurdles in the clinical trial process for ZIKV vaccines.
Main Results:
- Preclinical studies in animal models have shown promising results, indicating the feasibility of developing an effective ZIKV vaccine.
- Multiple vaccination strategies are under investigation, with varying degrees of success in early-stage research.
Conclusions:
- While ZIKV vaccine development is progressing, significant scientific and logistical challenges persist.
- Addressing these challenges is crucial for the successful clinical evaluation and deployment of a ZIKV vaccine to protect public health.
